Shares of Arrowhead Research (ARWR -13.8%) hit a new 52-week low earlier in the session after...

|About: Arrowhead Pharmaceuticals (ARWR)|By:, SA News Editor

Shares of Arrowhead Research (ARWR -13.8%) hit a new 52-week low earlier in the session after the company says it's entered into a $6.2M securities purchase agreement with several institutional and individual investors, including James Mellon, and a new fund dedicated to health care investments. The placement consists of 2.3M shares of common stock, and warrants to purchase 1.7M shares, with each unit priced at $2.76 and consisting of one share of common stock and a warrant worth 0.75 shares.